Rituximab for the first-line treatment of stage III-IV follicular lymphoma

7 Sources of evidence considered by the Committee

The assessment report for this appraisal was prepared by School of Health-Related Research (ScHARR):

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees, were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

Professional or specialist, and patient or carer groups:

Other consultees:

Commentator organisations (without the right of appeal):

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on rituximab by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

Representatives from the following manufacturers or sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.